title: [Therapeutic study of leukemia by pegylated liposomal daunorubicin].
abstract: OBJECTIVE
  To explore the antitumor effect and toxicity of pegylated liposomal daunorubicin (PL-DNR) on leukemia.
  
  
  METHODS
  PL-DNR was prepared by dry lipid hydration and remote loading, and its physicochemical indexes were analyzed. The inhibiting effect of PL-DNR on leukemia cells was observed in terms of in vitro cytotoxicity experiment. The therapeutic effect in vivo was assessed by tumor inhibition in leukemia L1210-bearing mice. Apoptosis in cardiomyocytes was detected using the terminal deoxynucleotidyl transferase mediated dUTP nick end labeling method (TUNEL staining).
  
  
  RESULTS
  The average diameter of PL-DNR was (110 ± 10)nm and the encapsulation efficiency was 94.21%. The in vitro cytotoxicity experiment showed that the inhibiting ability of PL-DNR in the treatment groups was continuously enhanced as the experiment proceeded. The in vivo pharmacodynamic experiment also indicated obvious tumor-inhibiting effect of PL-DNR. At the end of the experiment, the tumor volume of the PL-DNR group was (433.71 ± 234.77)mm(3), significantly smaller than that of (1 293.77 ± 381.26) mm(3) in the DNR group (P < 0.05). Moreover, the tumor weight of the PL-DNR group was (0.66 ± 0.29)g and that of the DNR group was (1.25 ± 0.43)g (P < 0.05). The myocardial toxicity experiment showed that the median apoptosis index of cardiomyocytes in the PL-DNR group was 13.83%, significantly lower than that of 42.67% in the DNR group (P < 0.05), indicating a lower toxicity of PL-DNR to the myocardium.
  
  
  CONCLUSIONS
  Compared with the free DNR, PL-DNR can improve the therapeutic effect on leukemia and reduce the.
authors.affiliation: Cancer Hospital, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
authors.forename: Yongming
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Cancer Hospital, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
authors.forename: Xinghua
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Cancer Hospital, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
authors.forename: Wanyan
authors.initials: W
authors.lastname: Tang
authors.affiliation: Cancer Hospital, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China. Email: majie@cicams.ac.cn.
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017209:Apoptosis; D003630:Daunorubicin / Q000627:therapeutic use*; D007938:Leukemia / Q000628:therapy*; D051379:Mice
chemical_list: D000903:Antibiotics, Antineoplastic; D003630:Daunorubicin